Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.44 -0.4%	$2.88	$1.84 ▼ $5.31	$84.64M	1.3	518,323 shs	721,129 shs
AGEN Agenus	$4.81 +12.6%	$5.42	$1.38 ▼ $7.34	$131.89M	1.62	842,477 shs	949,637 shs
DOMH Dominari	$6.67 +25.1%	$5.25	$0.83 ▼ $13.58	$97.65M	0.5	917,238 shs	1.13 million shs
VICL Vical		$1.24	$0.60 ▼ $1.47	$21.01M	0.32	1.44 million shs	35,024 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-2.00%	-5.04%	+5.60%	-7.55%	-42.76%
AGEN Agenus	-11.04%	-20.93%	-39.52%	+26.33%	-16.11%
DOMH Dominari	-6.98%	+6.18%	+6.81%	-6.82%	+237.34%
VICL Vical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	2.2373 of 5 stars	3.8	2.0	0.0	0.0	2.8	0.0	0.6
AGEN Agenus	4.2733 of 5 stars	3.3	4.0	0.0	4.6	2.4	1.7	0.6
DOMH Dominari	1.1571 of 5 stars	0.0	3.0	0.0	0.0	2.4	2.5	0.6
VICL Vical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	487.43% Upside
AGEN Agenus	2.67	Moderate Buy	$16.33	239.57% Upside
DOMH Dominari	0.00	N/A	N/A	N/A
VICL Vical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VICL, ACHV, AGEN, and DOMH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/13/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/13/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.61 per share	N/A
AGEN Agenus	$103.46M	1.27	N/A	N/A	($13.06) per share	-0.37
DOMH Dominari	$18.15M	5.38	N/A	N/A	$5.71 per share	1.17
VICL Vical	$1.62M	0.00	N/A	N/A	$1.82 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.46	N/A	N/A	N/A	N/A	-193.49%	-116.68%	N/A
AGEN Agenus	-$227.21M	-$8.67	N/A	N/A	N/A	-196.12%	N/A	-82.33%	N/A
DOMH Dominari	-$14.70M	-$4.50	N/A	∞	N/A	-167.73%	-91.67%	-77.80%	8/14/2025 (Estimated)
VICL Vical	-$16.25M	-$0.81	N/A	N/A	N/A	-1,002.10%	-29.46%	-27.85%	N/A

Latest VICL, ACHV, AGEN, and DOMH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AGEN Agenus	-$0.78	-$1.00	-$0.22	-$1.00	$49.71 million	$25.70 million
8/11/2025	Q2 2025	DOMH Dominari	N/A	-$1.02	N/A	$1.12	N/A	$34.10 million
8/7/2025	Q2 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/13/2025	Q1 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
DOMH Dominari	N/A	N/A	N/A	N/A	N/A
VICL Vical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.21	6.64	6.64
AGEN Agenus	N/A	0.11	0.11
DOMH Dominari	N/A	5.74	5.74
VICL Vical	N/A	36.84	36.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
AGEN Agenus	61.46%
DOMH Dominari	42.48%
VICL Vical	29.06%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
AGEN Agenus	5.50%
DOMH Dominari	32.98%
VICL Vical	4.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
DOMH Dominari	4	14.64 million	9.81 million	Not Optionable
VICL Vical	30	22.84 million	N/A	Not Optionable

VICL, ACHV, AGEN, and DOMH Headlines

Recent News About These Companies

Mattr introduces VICAL Viewer to ease mDL adoption for relying parties

September 11, 2024 | biometricupdate.comB

Vical Announces Review of Potential Strategic Transactions

August 17, 2024 | br.advfn.com

Vical Reports Third Quarter 2018 Financial and Operational Results

August 17, 2024 | br.advfn.com

Fresh Tracks Therapeutics (FRTX) Earnings Dates & Reports

May 26, 2024 | investing.com

Evan Gershkovich’s sister was the quiet one. Now she’s his voice.

March 29, 2024 | msn.com

Video: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s Song

March 29, 2024 | ijr.comI

Song Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, more

March 29, 2024 | msn.com

Song lyrics getting simpler, more repetitive, angry and self-obsessed – study

March 29, 2024 | theguardian.com

Beyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’

March 29, 2024 | msn.com

Beyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist?

March 29, 2024 | msn.com

Creed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream team

March 28, 2024 | msn.com

BBC stands by replacing singer with AI-generated voice

March 28, 2024 | msn.com

Song Lyrics Really Are Getting Simpler and More Repetitive, Study Finds

March 28, 2024 | scientificamerican.comS

Funniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee'

March 28, 2024 | msn.com

Kanye wife Bianca Censori’s voice heard for first time in newly resurfaced video

March 28, 2024 | nydailynews.com

Top 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the list

March 28, 2024 | tennessean.comT

Song Lyrics Are Now More Repetitive and Simple, Study Confirms

March 28, 2024 | msn.com

KJP Declares Press Gaggle off the Record as Obama’s Voice Is Heard

March 28, 2024 | ijr.comI

Song lyrics have become angrier since the 80s, study shows

March 28, 2024 | msn.com

Boston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgery

March 28, 2024 | baltimoresun.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VICL, ACHV, AGEN, and DOMH Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.44 -0.01 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.46%)

As of 07:55 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Agenus NASDAQ:AGEN

$4.81 +0.54 (+12.65%)

Closing price 04:00 PM Eastern

Extended Trading

$4.78 -0.03 (-0.71%)

As of 07:27 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Dominari NASDAQ:DOMH

$6.67 +1.34 (+25.14%)

As of 04:00 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Vical NASDAQ:VICL

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time